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Vascularized bone grafting is widely used to treat massive bone defects following trauma or 27 turner resection, osteomyelitis, or osteonecrosis, and is also useful for difficult situations in 28 hand surgery. Although vascularized bones contain high osteogenic potential, the graft 29 procedure is associated with difficult harvesting and complications at donor sites [ 1, 2] . 30 Artificial bone material has gained attention as an implant that differs from metallic and 31 polymeric materials in its superior compatibility with in vivo bone; therefore, it has a broad 32 range of clinical applications [3, 4] . Although the material possesses some osteoinductive and 33 osteoconductive activity, the osteogenic potential of artificial bone is limited [5] . Factors 34 enhancing neovascularization are required for new bone formation in artificial bone materials 35 to promote osteogenic differentiation and proliferation. 36 Previous research has explored methods to enhance neovascularization within artificial bone. 37 Tissue-engineered techniques, in which bone marrow stromal cells (BMSCs) or growth 38 factors are added to artificial bone [6-9], have enabled new procedures for bone regeneration. 39 Although there have been several clinical trials using tissue-engineered bone (TEB) grafts [1 0, 40 11 ], we know of no previous studies treating patients with massive bone defects using TEB 41 grafts, particularly in poorly vascularized areas occurring post irradiation or infection-derived 42 scarring lesions. 43 In a previous study, bone regeneration was promoted by inserting vascular bundles into 44 tissue-engineered madreporic coral implants [12] , and several subsequent studies have been 45 performed to expedite vascularization of TEB grafts [13] [14] [15] [16] [17] . These studies included methods antibiotics (100-U/ml penicillin and 100-11g/ml streptomycin; Nacalai Tesque, Kyoto, Japan).
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Cells were cultured in a humidified atmosphere of 95% air and 5% C02 at 37 °C. 
BMSC transfer onto P-TCP
111
The cylindrical ~-TCP ceramic scaffold was prepared by HOYA Corporation (Tokyo, Japan). 
Conclusions
251
In this study, we demonstrated that using OMCS with a vascular bundle in the center of a~-
252
TCP scaffold maintained a high angiogenic and osteogenic potential 4 weeks after .... (' .
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